Measurement-Based Quantum Computation on Symmetry Breaking Thermal States

We consider measurement-based quantum computation (MBQC) on thermal states of the interacting cluster Hamiltonian containing interactions between the cluster stabilizers that undergoes thermal phase transitions. We show that the long-range order of the symmetry breaking thermal states below a critical temperature drastically enhance the robustness of MBQC against thermal excitations. Specifically, we show the enhancement in two-dimensional cases and prove that MBQC is topologically protected below the critical temperature in three-dimensional cases. The interacting cluster Hamiltonian allows us to perform MBQC even at a temperature an order of magnitude higher than that of the free cluster Hamiltonian.Comment: 8 pages, 7 figure

Evaluation of ambipolar carrier mobility in alkyl-substituted phthalocyanine thin film

Yuki Nishikawa, Yuya Nakata, Shigehiro Ikehara, Akihiko Fujii, and Masanori Ozaki "Evaluation of ambipolar carrier mobility in alkyl-substituted phthalocyanine thin film," Journal of Photonics for Energy 8(3), 032214 (15 May 2018). DOI: https://doi.org/10.1117/1.JPE.8.03221

3-D finite element analysis of coupling current in multifilamentary AC superconducting cable

A method for analyzing the 3-D coupling current which is induced by an AC magnetic field in a multifilamentary superconducting cable is developed. In this method, such a superconducting cable, in which many twisted filaments are embedded in a matrix, is treated as macroscopic, having anisotropic conductivity. The method for treating the anisotropy of conductivity and the 3-D finite-element formulation are presented. The effectiveness of the technique is illustrated by the analysis of the 3-D coupling currents of superconducting cables.</p

Immuno-chemotherapy of malignant lymphoma using OK-432, a streptococcal agent

Clinical trials of immuno-chemotherapy were conducted on malignant lymphoma patients. Patients during the period from 1972 through 1977 were allocated to two groups retrospectively according to the mode of treatment, i.e., chemotherapy alone (historical control group, 35 patients) and chemotherapy with OK-432 (treated group, 15 patients). Comparisons were made of the two groups, which were homogeneous with regard to induction chemotherapy, maintenance chemotherapy, stage and histologic type of disease. The treated group had a higher remission rate, and a longer remission duration and survival than the control groups, especially in patients with Hodgkin's disease but the difference was not statistically significant owing to the limited number of cases.</p

Study on cause of quenching at the joint between multifilamentary superconducting cable and normal conducting cable using 3D FEM

Investigates the cause of quenching at the joint between a multifilamentary superconducting cable and a normal conducting cable. The 3D current distribution is analyzed. It is found that the cause of quenching is the extreme concentration of current in the joint due to the pronounced skin effect at liquid helium temperature. The mechanism of the concentration of current which is affected by the twist pitch and skin depth is also clarified quantitatively by numerical analysis</p

A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis

In clinical studies, the next-generation anti-tumor necrosis factor-alpha (TNF-α) single domain antibody ozoralizumab showed high clinical efficacy shortly after the subcutaneous injection. To elucidate the mechanism underlying the rapid onset of the effects of ozoralizumab, we compared the biodistribution kinetics of ozoralizumab and adalimumab after subcutaneous injection in an animal model of arthritis. Alexa Fluor 680-labeled ozoralizumab and adalimumab were administered by subcutaneous injection once (2 mg/kg) at five weeks after induction of collagen-induced arthritis (CIA) in an animal arthritis model. The time-course of changes in the fluorescence intensities of the two compounds in the paws and serum were evaluated. The paws of the CIA mice were harvested at four and eight hours after the injection for fluorescence microscopy. Biofluorescence imaging revealed better distribution of ozoralizumab to the joint tissues than of adalimumab, as early as at four hours after the injection. Fluorescence microscopy revealed a greater fluorescence intensity of ozoralizumab in the joint tissues than that of adalimumab at eight hours after the injection. Ozoralizumab showed a significantly higher absorption rate constant as compared with adalimumab. These results indicate that ozoralizumab enters the systemic circulation more rapidly and is distributed to the target tissues earlier and at higher levels than conventional IgG antibodies. Our investigation provides new insight into the mechanism underlying the rapid onset of the effects of ozoralizumab in clinical practice.Oyama S., Ebina K., Etani Y., et al. A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. Scientific Reports 12, 18102 (2022); https://doi.org/10.1038/s41598-022-23152-6

Combination chemotherapy for small cell carcinoma of the lung: evaluation of four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine.

Forty-one patients with small cell carcinoma of the lung were treated with a four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine. The response rate was 68% (28 responded among 41 patients), with 10 complete responses (24%) and 18 partial responses (44%). The median survival time from the initiation of chemotherapy was 11 months for patients with limited disease and 8 months for those with extensive disease. Patients who achieved complete response survived significantly longer than those who did not; the median survival time for complete responders was 14.5 months, compared to 8.5 months for partial responders and 6 months for non-responders. Myelosuppressive toxicity remained within acceptable limits, with 5% incidence of leukocytopenia (less than 1,000/microliter) and 7% incidence of thrombocytopenia (less than 50,000/microliter) following the first course of the regimen.</p